EVP 6124 (EnVivo Pharma)success in Phase IIb Alzheimers Disease trial - 20-Jul-2012

EnVivo Pharmaceuticals, announced positive results from its Phase IIb clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's Disease during an oral presentation at the Alzheimer's Association International Conference 2012 being held in Vancouver, British Columbia. The six-month, double-blind Phase IIb clinical trial evaluated EVP-6124 against placebo in patients with mild to moderate Alzheimer's Disease. The EVP-6124 2.0 mg dose met both of the trial's primary endpoints with statistically significant positive effects on cognition (p=0.0189), as measured by the Alzheimer's Disease Assessment Scale-Cognitive subscale-13 (ADAS-Cog-13) and clinical function (p=0.0253) as measured by the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB). The data also showed statistically significant results across secondary endpoints of other cognitive and clinical measures. Importantly, EVP-6124 was generally safe and well-tolerated over the trial's six-month dosing period. Based on the Phase IIb trial results, EnVivo will continue to advance EVP-6124 and plans to initiate a Phase III clinical trial in Alzheimer's disease in 2013.